These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12538458)

  • 1. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
    Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
    Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma.
    Pagliaro L; Daliani D; Amato R; Tu SM; Jones D; Smith T; Logothetis C; Millikan R
    Cancer; 2000 Aug; 89(3):615-8. PubMed ID: 10931461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
    Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
    Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
    Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
    Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
    Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
    Zonder JA; Shields AF; Zalupski M; Chaplen R; Heilbrun LK; Arlauskas P; Philip PA
    Clin Cancer Res; 2001 Jan; 7(1):38-42. PubMed ID: 11205915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
    Van Veldhuizen PJ; Faulkner JR; Lara PN; Gumerlock PH; Goodwin JW; Dakhil SR; Gross HM; Flanigan RC; Crawford ED;
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):39-45. PubMed ID: 15791454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
    Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
    Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
    Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
    Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
    Amato RJ; Morgan M; Rawat A
    Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
    J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
    Davis NB; Taber DA; Ansari RH; Ryan CW; George C; Vokes EE; Vogelzang NJ; Stadler WM
    J Clin Oncol; 2004 Jan; 22(1):115-9. PubMed ID: 14701773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
    Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma.
    Clamp AR; Blackhall FH; Vasey P; Soukop M; Coleman R; Halbert G; Robson L; Jayson GC;
    Br J Cancer; 2003 Oct; 89(7):1152-4. PubMed ID: 14520436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program].
    Tourani JM; Jaillon-Abraham C; Lucas V; Chrétien Y; Mayeur D; Di Palma M; Boaziz C; Grise P; Varette C; Pavlovitch JM; Larregain D; Ecstein E; Untereiner M; Andrieu JM
    Bull Cancer; 1997 Apr; 84(4):351-6. PubMed ID: 9238157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.
    Blackhall FH; Ranson M; Radford JA; Hancock BW; Soukop M; McGown AT; Robbins A; Halbert G; Jayson GC;
    Br J Cancer; 2001 Feb; 84(4):465-9. PubMed ID: 11263437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study.
    Dutcher JP; Leon L; Manola J; Friedland DM; Roth B; Wilding G;
    Cancer; 2005 Dec; 104(11):2392-9. PubMed ID: 16222691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
    Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study.
    Stahl M; Schmoll E; Becker H; Schlichter A; Hoffmann L; Wagner H; Possinger K; Müller W; Köllermann M; Weidenhammer W
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):33-7. PubMed ID: 2031196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.